Boston Scientific Corporation $BSX Shares Sold by Synergy Asset Management LLC

Synergy Asset Management LLC cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 49.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 248,110 shares of the medical equipment provider’s stock after selling 245,213 shares during the quarter. Boston Scientific makes up 2.5% of Synergy Asset Management LLC’s portfolio, making the stock its 11th largest holding. Synergy Asset Management LLC’s holdings in Boston Scientific were worth $23,657,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. State Street Corp grew its holdings in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares during the period. Norges Bank purchased a new stake in shares of Boston Scientific in the second quarter valued at approximately $2,089,937,000. Invesco Ltd. raised its stake in shares of Boston Scientific by 0.7% during the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after buying an additional 111,826 shares during the period. Finally, Northern Trust Corp grew its stake in Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock valued at $1,406,129,000 after acquiring an additional 128,188 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Some analysts and commentators see a potential turn in fortunes or an eventual rating upgrade if execution improves, which supports a constructive long‑term thesis for BSX. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
• Neutral Sentiment: Analyst model adjustments have been modest — Erste trimmed a FY2027 EPS forecast slightly — indicating analysts are tightening growth assumptions rather than making sweeping downgrades. This is a modest headwind but not a major re‑rating event by itself.
• Negative Sentiment: Multiple law firms have filed or solicited plaintiffs in securities class actions alleging misstatements about U.S. electrophysiology procedure growth and related disclosures; the cases cover purchases from July 23, 2025 through Feb 3, 2026 and highlight a May 4, 2026 lead‑plaintiff deadline. This clustering increases legal and settlement risk and is weighing on the stock. BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
• Negative Sentiment: Several other firms issued investor alerts and lawsuits (Pomerantz, Portnoy, Bernstein Liebhard, Levi & Korsinsky, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Robbins Geller, etc.), reinforcing the coverage and media attention around litigation risk and potential shareholder losses. BSX Investor Alert: Securities Fraud Lawsuit (SueWallSt)
• Negative Sentiment: Market coverage of these developments coincided with recent share weakness and headlines noting sharper-than-market declines, which can amplify short‑term selling pressure as investors de‑risk exposure. Boston Scientific (BSX) Falls More Steeply Than Broader Market

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Up 0.4%

Shares of Boston Scientific stock opened at $70.08 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The stock’s 50 day simple moving average is $77.83 and its 200-day simple moving average is $91.10. The stock has a market cap of $104.16 billion, a P/E ratio of 36.13, a P/E/G ratio of 1.08 and a beta of 0.69. Boston Scientific Corporation has a 1-year low of $67.56 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wells Fargo & Company reduced their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Mizuho reduced their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. UBS Group lowered their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Stifel Nicolaus reduced their target price on Boston Scientific from $110.00 to $90.00 and set a “buy” rating for the company in a report on Friday, March 20th. Finally, The Goldman Sachs Group set a $99.00 price target on Boston Scientific in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $106.27.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.